ストックスクリーナーアプリを入手
4.76
4.62%
0.21
前日終値:
$4.55
開ける：
$4.54
24時間の取引高:
75,628
Relative Volume:
0.41
時価総額：
$111.66M
収益：
$7.94M
当期純損益:
$-21.13M
株価収益率:
-4.4001
EPS:
-1.0818
ネットキャッシュフロー:
$-16.17M
1週間 パフォーマンス:
+3.70%
1か月 パフォーマンス:
+4.16%
6か月 パフォーマンス:
-3.45%
1年 パフォーマンス:
-25.39%
1日の値動き範囲:
$4.52
$4.77
1週間の範囲:
$4.36
$4.77
52週間の値動き範囲:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.76 | 114.01M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-09 | 開始されました | Lake Street | Buy |
| 2024-12-04 | 開始されました | D. Boral Capital | Buy |
Coya Therapeutics Inc (COYA) 最新ニュース
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Coya Therapeutics (COYA) Holds Ground at $4.67 as Consolidation ContinuesOBV Divergence - vinanet.vn
Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" - CBS News
Coya Therapeutics (COYA) Edges Up 0.85% to $4.73, Holding Support Amid ConsolidationGEX Level - vinanet.vn
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss Offers a Favorable SurpriseNext Quarter Guidance - vinanet.vn
COYA Pulls Back to $4.69: Coya Therapeutics Approaches Critical Support LevelHigh Dividend Factor - vinanet.vn
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - Kalkine Media
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives 2.7% Stock UptickMargin Improvement Report - vinanet.vn
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Delivers 24.1% EPS Surprise, Shares Rise 2.7%Margin Expansion Trends - vinanet.vn
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 5.4%Net Profit Margin - vinanet.vn
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleNegative Gamma - vinanet.vn
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
COYA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineQuarterly Profit Report - vinanet.vn
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
COYA Q1 2026 Earnings: Narrower Loss Beats Street Estimate Amid Pre-Revenue ProgressOne-Time Loss Impact - vinanet.vn
COYA Q1 2026 Earnings: Narrower Loss Beats Estimates as Biotech Priorities Cash RunwaySlow Growth Warning - vinanet.vn
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
COYA Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Drives Cautious OptimismManagement Tone Analysis - vinanet.vn
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):